Provided by Tiger Trade Technology Pte. Ltd.

NovoCure

16.22
+0.07000.43%
Volume:1.64M
Turnover:26.66M
Market Cap:1.89B
PE:-12.40
High:16.55
Open:16.18
Low:16.01
Close:16.15
52wk High:21.45
52wk Low:9.82
Shares:116.45M
Float Shares:96.42M
Volume Ratio:1.50
T/O Rate:1.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3082
EPS(LYR):-1.2221
ROE:-43.22%
ROA:-9.26%
PB:5.59
PE(LYR):-13.27

Loading ...

Assessing NovoCure (NVCR) Valuation After Prolonged Share Price Weakness And Undervalued Narrative

Simply Wall St.
·
Apr 14

Earning Preview: NovoCure this quarter’s revenue is expected to increase by 14.50%, and institutional views are cautious

Earnings Agent
·
Apr 13

NovoCure Expands Executive Role, Adjusts CMO Compensation

TIPRANKS
·
Apr 10

Novocure pays CHF 5,000 monthly stipend for interim chief medical officer role

Reuters
·
Apr 10

Novocure price target lowered to $16 from $23 at Evercore ISI

TIPRANKS
·
Apr 06

NovoCure (NVCR) Jumps After Strong PANOVA-4 Data Validates TTFields Combo Potential In Pancreatic Cancer

Simply Wall St.
·
Apr 03

Novocure to report first-quarter results, host conference call and webcast

Reuters
·
Apr 01

Novocure to Report First Quarter 2026 Financial Results

THOMSON REUTERS
·
Apr 01

Zymeworks appoints Kristin Stafford as CFO effective April 1, 2026

Reuters
·
Apr 01

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Ongoing Middle East Tensions

MT Newswires Live
·
Mar 26

Novocure reports PANOVA-4 primary endpoint met; disease control rate rises to 74.4% from 48% in historical control

Reuters
·
Mar 26

Novocure Ltd - Ttfields Therapy Well-Tolerated With Device Safety Consistent With Prior Studies

THOMSON REUTERS
·
Mar 26

Novocure Announces Positive Topline Results From Phase 2 Panova-4 Clinical Trial of Tumor Treating Fields (Ttfields) Therapy for Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Mar 26

Novocure Ltd - Panova-4 Meets Primary Endpoint With Dcr of 74.4% VS 48% in Historical Control

THOMSON REUTERS
·
Mar 26